Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications

International Journal of Clinical Practice

Volumn 67, Issue 2, 2013, Pages 170-180

  Bennie, M ^a,b   Bishop, I ^b   Godman, B ^c,d,e   Barbui, C ^f   Raschi, E ^g   Campbell, S ^h   Miranda, J ⁱ   Gustafsson, L L ^c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b INFORMATION SERVICES DIVISION   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^f UNIVERSITY OF VERONA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; GENERIC DRUG; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZOTEPINE;

ARTICLE; DRUG COST; DRUG UTILIZATION; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM;

ANTIPSYCHOTIC AGENTS; DRUG UTILIZATION; DRUGS, GENERIC; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; REIMBURSEMENT MECHANISMS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SCOTLAND;

EID: 84872348750     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12100     Document Type: Article

References (98)

1. Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P,. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev Pharmacoeconomcis Outcomes Res 2008; 8: 357-71.
2. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP,. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl Health Econ Health Policy 2010; 8: 7-24.
3. Coma A, Zara C, Godman B, et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 569-81.
4. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V,. Recent national and regional drug reforms in Sweden-implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008; 26: 537-50.
5. Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, et al. Use of generics-a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 2010; 3: 2470-94. doi: 10.3390/ph/3082470 ISSN 1424-8247.
6. Vončina L, Strizrep T, Godman B, et al. Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe; implications for the future. Expert Rev Pharmacoeconomics and Outcomes Res 2011; 11: 469-79.
7. Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev Pharmacoeconomics Outcomes Res 2010; 10: 707-22.
8. Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Frontiers Pharmacol 2011; 1: 1-16. doi: 10.3389/fphar.2010.00141.
9. Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL,. Enhancing the rational use of new medicines across European healthcare systems-a position paper. Eur J Clin Pharmacol 2008; 64: 1137-8.
10. Godman B, Haycox A, Schwabe U, et al. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 2008; 26: 91-8.
11. Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B,. Potential savings without compromising the quality of care. Int J Clin Pract 2009; 63: 1320-6.
12. Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A,. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res 2011; 11: 121-9.
13. Godman B, Malmstrom RE, Bennie M, Sakshaug S, Burkhardt T., et al. Prescribing restrictions-a necessary strategy among some European countries to enhance future prescribing efficiency? Rev Health Care 2012; 3: 5-16.
14. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A,. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK; impact and implications. Expert Rev Pharmacoecon Outcomes Res 2010; 10: 73-85.
15. Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, et al. The "Wise List"-a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011; 108: 224-33.
16. Bennie M, Godman B, Bishop I, Campbell S,. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 125-30.
17. Garuoliene K, Godman B, Gulbinovič J, Wettermark B, Haycox A,. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoeconomics Outcomes Res 2011; 11: 343-9.
18. Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A,. Generic olanzapine: health authority opportunity or nightmare? Expert Rev Pharmacoecon Outcomes Res 2008; 8: 549-55.
19. SIGN. Dyspepsia-a national clinical guideline. March 2003. Available via URL: http://www.sign.ac.uk/pdf/sign68.pdf (accessed December 2012).
20. SIGN. Secondary prevention of CHD following Myocardial Infarction. 2000. Available via URL: http://www.nhsggc.org.uk/content/mediaassets/pdf/HSD/sign41. pdf (accessed December 2012).
21. SIGN. Management of Diabetes. 2010 Available via URL: http://www.sign.ac.uk/sign116.pdf (accessed December 2010).
22. Wladysiuk M, Araszkiewicz A, Godman B, Szabert K, et al. Patient co-payments do influence atypical antipsychotic choice in Poland; implications once generic atypcials are available. Appl Health Econ Health Policy 2011; 9: 101-10.
23. Knapp M, Kanavos P, King D, et al. Economic issues in access to medications: schizophrenia treatment in England. Int J Law Psychiatry 2005; 28: 514-31.
24. Mirandola M, Andretta M, Corbari L, et al. Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002. Pharmacoepidemiol Drug Saf 2006; 15: 412-20.
25. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff 2009; 28: 770-81.
26. NICE implementation uptake report: atypical antipsychotic drugs for the treatment of schizophrenia. NICE Technology appraisals 43. Available via URL: http://www.nice.org.uk/media/410/E9/ImplUptakeReportAtypicalAntipsychotics.pdf
27. Mond J, Morice R, Owen C, et al. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003; 37: 55-61.
28. Leucht S, Corvers C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
29. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU,. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 2011; doi: 10.1038/mp.2011.143. [Epub ahead of print].
30. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS,. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011; 20: 177-84.
31. Leslie D, Rosenheck R,. Off-label use of antipsychotic medications in medicaid. Am J Manag Care 2012; 18: e109-17.
32. Fisk M, Feeley J, Voreacos D., J&J Said to Agree to $2.2 Billion Drug Marketing Accord. Available via URL: (http://www.bloomberg.com/ news/2012-06-11/j-j-said-to-pay-2-2-billion-to-end-risperdal-sales-probe.html (accessed September 2012).
33. Department of Justice settlement agreement. Available via URL: http://www.justice.gov/usao/pae/Pharma-Device/astrazeneca-settlementagreement. pdf (accessed September 2012).
34. Jack A,. AstraZeneca faces $520 m Seroquel fine. Available via URL: http://www.ft.com/cms/s/0/319e31d4-5251-11df-8b09-00144feab49a. html#axzz26q1gMSgc (accessed September 2012).
35. Ren XS, Qian S, Lee AF, et al. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. J Clin Pharm Ther 2006; 31: 57-65.
36. Taylor DM, Wright T, Libretto S,. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry 2003; 64: 589-97.
37. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255-64.
38. Walley T,. Neuropsychotherapeutics in the UK. What has been the impact of NICE on prescribing? CNS Drugs 2004; 18: 1-12.
39. NICE. Schizophrenia-Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE ClinicalGuideline 82. Issued March 2009. Available via URL: http://www.nice.org.uk/nicemedia/live/ 11786/43610/43610.pdf
40. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-9.
41. Tyrer P, Kendall T,. The spurious advance of antipsychotic drug therapy. Lancet 2009; 373: 4-5.
42. Gardner D, Baldessarini RJ, Waraich P,. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703-11.
43. Andretta M, Ciuna A, Corbari L, et al. Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. Soc Psychiatry Psychiatr Epidemiol 2005; 40: 72-7.
44. Titier K, Girodet PO, Verdoux H, Molimard M, et al. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf 2005; 28: 35-51.
45. Haddad PM, Sharma SG,. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911-36.
46. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. NEJM 2009; 360: 225-35.
47. Vieweg WV, Wood MA, Fernandez A,. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009; 26: 997-1012.
48. Poluzzi E, Raschi E, Moretti U, De Ponti F,. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009; 18: 512-8.
49. Meyer-Massetti C, Vaerini S, Rätz Bravo AE, et al. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int J Clin Pharm 2011; 33: 806-14.
50. Tiihonen J, Lönnqvist J, Wahlbeck W, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-627.
51. US FDA. Information for Healthcare Professionals: Conventional Antipsychotics. Available via URL: http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ucm124830.htm (accessed September 2012).
52. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
53. Lieberman JA, Stroup T,. Commentary-the NIM H-CAT ie schizophrenia study: what did we learn? Am J Psychiatry 2011; 168: 770-5.
54. Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP,. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. J Clin Psychiatry 2012; 73: 498-503. Epub 2011 Dec 13
55. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; March 17; (3): CD006654. doi: 10.1002/14651858.CD006654.pub2
56. Komossa K, Rummel-Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2011; Jan 19; (1) CD006626. doi: 10.1002/14651858.CD006626.pub2
57. Hargreaves WA, Gibson JP,. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs 2005; 19: 393-410.
58. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163: 185-94.
59. Essock SM, Covell NH, Davis SM, Stroup TS, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006; 163: 2090-5.
60. Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 2009; 107: 22-9.
61. Magnus A, Carr V, Mihalopoulos C, et al. Assessing cost-effectiveness of drug interventions for schizophrenia. Aust N Z J Psychiatry 2005; 39: 44-54.
62. Glick ID, Stekoll AH, Hays S,. The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia. J Clin Psychopharmacol 2011; 31: 82-5.
63. Healy DJ, Taylor S, Goldman M, Barry K, Blow F, Milner KK,. Clinical equivalence of generic clozapine. Community Ment Health J 2005; 41: 393-8.
64. Alessi-Severini S, Honcharik PL, Simpson KD, Eleff MK, Collins DM,. Evaluation of an interchangeability switch in patients treated with clozapine: a retrospective review. J Clin Psychiatry 2006; 67: 1047-54.
65. Paton C,. Generic clozapine: outcomes after switching. Br J Psychiatry 2006; 89: 184-5.
66. Bazire S, Burton V,. Generic clozapine in schizophrenia: what is all the fuss about? Pharmaceutical J 2004; 173: 720-1.
67. Khorana N, Maphanta S, Lohitnavy O, Srichaiya A, Sayasathid J,. Comparative pharmacokinetics and bioequivalence of two tablet formulations of 2 mg risperidone in healthy Thai male volunteers. Int J Clin Pharmacol Ther 2011; 49: 409-14.
68. Correl C, Carbon M,. Brand vs. generic psychotropic medication. Is one better than the other? Available via URL: https://www.nwpmd.com/LinkClick.aspx? fileticket=vr6K7kfBUfc%3D&tabid=342. (accessed December 2012).
69. Desmarais JE, Beauclair L, Margolese HC,. Switching from brand-name to generic psychotropic medications: a literature review. CNS Neurosci Ther 2011; 17: 750-60. doi: 10.1111/j.1755-5949.2010.00210.x. Epub 2010 Nov 30.
70. Moon J, Flett A, Godman B, Grosso A, Wierzbicki A,. Getting better value from the NHS drug budget. BMJ 2011; 342: 30-2.
71. Hems S., WHO model list of essential medicines and developed countries: a comparison with the Lothian joint formulary. WHO Drug Information 2006; 20: 73-7.
72. Lothian Formulary. Available via URL: http://www.ljf.scot.nhs.uk/ LothianJointFormularies/Adult/4.0/4.2/4.2.1/(a)/Pages/default.aspx (accessed December 2012).
73. Holden J,. Hawthorne effects and research into clinical practice. J Eval Clin Practice 2001; 7: 65-70.
74. Konstantinou G,. Pragmatic trials: how to adjust for the 'Hawthorne effect'? Thorax 2011;-: 1. doi: 10.1136/thoraxjnl-2011-200657.
75. Trietsch J, van der Weijden T, Verstappen W, et al. A cluster randomized controlled trial aimed at implementation of local quality improvement collaboratives to improve prescribing and test ordering performance of general practitioners: Study Protocol. Implement Sci 2009; 4: 6. doi: 10.1186/1748-5908-4-6
76. Verstappen WHJM, van der Weijden T, ter Riet G, Grimshaw J, Winkens R, Grol R,. Block design allowed for control of the Hawthorne effect in a randomized controlled trial of test ordering. J Clin Epidemiol 2004, 57: 1119-23
77. Godman B,. Actions to improve the efficient and safe use of drugs: what can we learn from international experiences? 8th Conference of Discussion of Pharmaceutical Spending on Health Managers and Their Impact on Sustainability of the System and 6th Conference of Debate on the Effectiveness and Safety in the Use of Drugs-http://www10.gencat.cat/catsalut/archivos/jornades/farmacia/8a/ Conferencia-inaugural-Godman.pdf (accessed September 2012).
78. World Health Organisation (WHO) Guidelines for ATC Classification and DDD Assignment 2009. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. www.whocc.no (accessed March 2012).
79. World Health Organization (WHO). Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330) Available via URL: http://www.who.int/ medicines/areas/quality-safety/safety-efficacy/Drug%20utilization%20research. pdf (accessed March 2012).
80. Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; Nov 10; (11): CD006633.
81. Leucht S, Heres S, Kissling W, Davis JM,. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2011; 14: 269-84. Epub 2011 Jan 6.
82. Raja M,. Clozapine safety, 35 years later. Curr Drug Saf 2011; 6: 164-84.
83. Vlahovic-Palcevski V, Gantumur M, Radosevic N, et al. Coping with changes in defined daily dose in longitudinal drug consumption databases. Pharm World Sci 2010; 32: 125-9.
84. McDowall D, McCleary R, Meidinger EE, Hay RA,. Interrupted time series analysis. In: Sage University Papers Series on Quantitative Applications in the Social Sciences. Thousand Oakes, CA: Sage Publications Inc, 1980: 07-021.
85. Ross-Degnan D, Soumerai SB, Fortess EE, Gurwitz JH,. Examining product risk in context. Market withdrawal of zomepirac as a case study. J Am Med Assoc 1993; 270: 1937-42.
86. Durbin J, Watson GS,. Testing for serial correlation in least square regression. Biometrika 1951; 37: 409-28.
87. Brennan P, Croft P,. Interpreting the results of observational research: chance is not such a fine thing. BMJ 1994; 309: 727-30.
88. Vogler S, Zimmermann N, Leopold C, de Joncheere K,. Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev 2011; 4: 22-32.
89. Maher AR, Maglione M, Bagley S, Suttorp M, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306: 1359-69.
90. Scottish Quality Prescribing Initiative. 2012. Available via URL: www.sehd.scot.nhs.uk/pca/PCA2012(M)08.pdf (accessed May 2012).
91. Chue P, Chue J,. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Exp Rev Pharmacoecon Outcome Res 2012; 12: 259-69.
92. Lambert T, Emmerson B, Hustig H,. Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. BMC Psychiatry 2012; 12: 25.
93. Willis M, Svensson M, Löthgren M, Eriksson B, et al. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ 2010; 11: 585-94.
94. Rosenheck RA, Barnett PG, Hicks P, Krystal JH, Lew R, et al. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry 2012; 73: 696-702.
95. Covell NH, McEvoy JP, Schooler NR, et al. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry 2012; 73: 669-75.
96. Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V,. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 2009; 120: 97-101.
97. Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ,. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands. Clin Ther 2010; 32: 108-18.
98. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010; 35: 2367-77.